Get the Stockscreener App
11.33
6.59%
0.70
After Hours:
11.33
Daxor Corporation stock is traded at $11.33, with a volume of 7,931.
It is up +6.59% in the last 24 hours and up +17.29% over the past month.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
See More
Previous Close:
$10.63
Open:
$10.45
24h Volume:
7,931
Relative Volume:
0.29
Market Cap:
$54.80M
Revenue:
$2.61M
Net Income/Loss:
$1.69M
P/E Ratio:
37.73
EPS:
0.3003
Net Cash Flow:
-
1W Performance:
+0.44%
1M Performance:
+17.29%
6M Performance:
+50.27%
1Y Performance:
+23.56%
1-Day Range:
$10.27
$11.33
1-Week Range:
$10.00
$11.35
52-Week Range:
$6.55
$11.38
Daxor Corporation Stock (DXR) Company Profile
Name
Daxor Corporation
Sector
Industry
Phone
212-330-8500
Address
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Compare DXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
11.33 | 51.71M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
454.52 | 168.15B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
191.26 | 53.93B | 21.39B | 1.61B | 2.55B | 5.56 |
|
RMD
Resmed Inc
|
273.81 | 39.68B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ALC
Alcon Inc
|
78.91 | 38.70B | 10.03B | 1.07B | 1.39B | 2.17 |
|
WST
West Pharmaceutical Services Inc
|
247.54 | 17.53B | 2.96B | 487.70M | 344.00M | 6.68 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-19 | Initiated | Ascendiant Capital Markets | Buy |
Daxor Corporation Stock (DXR) Latest News
Can Daxor Corporation deliver consistent EPS growthQuarterly Performance Summary & High Accuracy Investment Entry Signals - khodrobank.com
Understanding Daxor Corporation’s price movementJuly 2025 PreEarnings & Real-Time Price Movement Reports - Newser
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Blood Volume Tech Leader Daxor Corporation to Present at Major Global Investment Conference in NYC - Stock Titan
Daxor Corporation stock retracement – recovery analysisTrade Risk Report & Reliable Entry Point Alerts - Newser
Does Daxor Corporation qualify in momentum factor screeningMarket Growth Summary & Reliable Breakout Stock Forecasts - Newser
Applying Elliott Wave Theory to Daxor Corporation2025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
What momentum shifts mean for Daxor CorporationJuly 2025 Highlights & Real-Time Volume Analysis - Newser
Analyzing Daxor Corporation with risk reward ratio chartsJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - Newser
Can Daxor Corporation withstand a market correctionWeekly Trend Recap & Expert Curated Trade Ideas - khodrobank.com
Will Daxor Corporation benefit from AI trendsJuly 2025 Movers & Safe Entry Momentum Stock Tips - khodrobank.com
Daxor reports increase in NAV to $7.15 per share - TipRanks
Has Daxor Corporation formed a bullish divergenceQuarterly Portfolio Report & AI Powered Market Entry Strategies - Newser
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter - The Manila Times
Daxor Corp reports mid-year update, significant progress in blood volume measurement technology. - AInvest
Published on: 2025-09-02 07:04:39 - Newser
3X Faster Blood Analysis: Daxor's New FDA-Cleared Device Drives 73% Revenue Jump in Game-Changing H1 - Stock Titan
What candlestick patterns are forming on Daxor Corporation2025 Risk Factors & AI Based Buy and Sell Signals - Newser
How to forecast Daxor Corporation trends using time seriesQuarterly Profit Report & Expert Approved Momentum Ideas - Newser
Does Daxor Corporation fit your quant trading modelWeekly Risk Report & AI Powered Trade Plan Recommendations - Newser
Live market analysis of Daxor CorporationQuarterly Portfolio Report & High Accuracy Buy Signal Tips - Newser
Is Daxor Corporation in a long term uptrendQuarterly Profit Review & Community Consensus Trade Alerts - khodrobank.com
Combining machine learning predictions for Daxor CorporationJuly 2025 Gainers & Safe Entry Trade Signal Reports - Newser
Chart based analysis of Daxor Corporation trends2025 Market Outlook & Expert Curated Trade Setups - Newser
Using data models to predict Daxor Corporation stock movementQuarterly Portfolio Review & High Accuracy Swing Trade Signals - Newser
Published on: 2025-09-01 11:16:03 - Newser
Is it time to cut losses on Daxor Corporation2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Analyzing drawdowns of Daxor Corporation with statistical tools2025 Price Action Summary & Weekly Consistent Profit Watchlists - Newser
AI Tools Suggest Daxor Corporation May Outperform This Week getLinesFromResByArray error: size == 0 - kangso.co.kr
Using economic indicators to assess Daxor Corporation potentialJuly 2025 PreEarnings & Consistent Profit Trading Strategies - Newser
Daxor Corporation stock chart pattern explainedWeekly Investment Summary & AI Forecasted Entry and Exit Points - Newser
Applying sector rotation models to Daxor CorporationRisk Management & Reliable Entry Point Trade Alerts - Newser
What the charts say about Daxor Corporation today2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Short Interest Drops in Daxor Corporation After Rally getLinesFromResByArray error: size == 0 - thegnnews.com
Daxor Corporation Stock (DXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):